STAAR Surgical Company (STAA) |
| 22.41 -0.035 (-0.16%) 09-16 16:00 |
| Open: | 22.62 |
| High: | 22.97 |
| Low: | 22.29 |
| Volume: | 711,048 |
| Market Cap: | 1,116(M) |
| PE Ratio: | 39.32 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 26.25 |
| Resistance 1: | 24.54 |
| Pivot price: | 23.03 |
| Support 1: | 21.77 |
| Support 2: | 18.11 |
| 52w High: | 35.87 |
| 52w Low: | 15.59 |
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
| EPS | 0.080 |
| Book Value | 7.290 |
| PEG Ratio | 0.76 |
| Gross Profit | 5.189 |
| Profit Margin (%) | 1.13 |
| Operating Margin (%) | 10.89 |
| Return on Assets (ttm) | 5.7 |
| Return on Equity (ttm) | 1.1 |
Tue, 15 Sep 2026
Is STAAR Surgical (STAA) A Bargain Following Its Profit Turnaround And China Led Sales Rebound? - simplywall.st
Mon, 14 Sep 2026
China-Led Rebound and New Leadership Might Change The Case For Investing In STAAR Surgical (STAA) - Yahoo Finance
Mon, 14 Sep 2026
STAAR Surgical (STAA) Swings To Profit, Is A 22% Undervalued View Justified? - Yahoo Finance
Mon, 14 Sep 2026
STAAR Surgical (STAA) Swings To Profit On China Rebound - Yahoo Finance
Fri, 11 Sep 2026
STAAR Surgical (STAA) Says Implantable Lenses Are Taking Share From Laser Surgery - simplywall.st
Fri, 11 Sep 2026
Staar Surgical Co (STAA) Shares Fall 3.4% -- What GF Score of 81 Tells Investors - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |